Toyota|$17.87 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.96 (¥4,265)+2.97%▲ (in JPY terms)
SoftBank|$21.84 (¥3,455)-2.65%▼ (in JPY terms)
MUFG|$21.40 (¥3,386)+5.02%▲ (in JPY terms)
Keyence|$461.31 (¥72,990)+4.65%▲ (in JPY terms)
Nintendo|$54.36 (¥8,601)+5.17%▲ (in JPY terms)
NTT|$1.04 (¥164)+2.62%▲ (in JPY terms)
Takeda|$42.15 (¥6,669)+1.66%▲ (in JPY terms)
Tokyo Electron|$54.70 (¥8,655)+4.74%▲ (in JPY terms)
Recruit|$111.33 (¥17,615)+3.62%▲ (in JPY terms)
ITOCHU|$14.80 (¥2,341)+4.46%▲ (in JPY terms)
Honda|$11.89 (¥1,882)+2.79%▲ (in JPY terms)
Shin-Etsu|$34.62 (¥5,477)+3.11%▲ (in JPY terms)
Tokio Marine|$3.69 (¥584)+2.56%▲ (in JPY terms)
Fast Retailing|$509.60 (¥80,630)+3.44%▲ (in JPY terms)
Toyota|$17.87 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.96 (¥4,265)+2.97%▲ (in JPY terms)
SoftBank|$21.84 (¥3,455)-2.65%▼ (in JPY terms)
MUFG|$21.40 (¥3,386)+5.02%▲ (in JPY terms)
Keyence|$461.31 (¥72,990)+4.65%▲ (in JPY terms)
Nintendo|$54.36 (¥8,601)+5.17%▲ (in JPY terms)
NTT|$1.04 (¥164)+2.62%▲ (in JPY terms)
Takeda|$42.15 (¥6,669)+1.66%▲ (in JPY terms)
Tokyo Electron|$54.70 (¥8,655)+4.74%▲ (in JPY terms)
Recruit|$111.33 (¥17,615)+3.62%▲ (in JPY terms)
ITOCHU|$14.80 (¥2,341)+4.46%▲ (in JPY terms)
Honda|$11.89 (¥1,882)+2.79%▲ (in JPY terms)
Shin-Etsu|$34.62 (¥5,477)+3.11%▲ (in JPY terms)
Tokio Marine|$3.69 (¥584)+2.56%▲ (in JPY terms)
Fast Retailing|$509.60 (¥80,630)+3.44%▲ (in JPY terms)

2026-09-18 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorization of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for cisplatin-treated muscle-invasive bladder cancer.”

2026-09-18 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorization of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for cisplatin-treated muscle-invasive bladder cancer.”

コメントする